Loading...
•
Dec 31, 2021
Curis Q4 2021 Earnings Report
Reported fourth quarter and year end financial results
Key Takeaways
Curis reported a net loss of $13.6 million, or $0.15 per share, for the fourth quarter of 2021. The company's cash, cash equivalents and investments totaled $139.8 million as of December 31, 2021, and it expects to maintain planned operations into 2024.
Presented positive updated data in Phase 1/2 TakeAim Leukemia study of CA-4948 Monotherapy.
Presented initial clinical data from Phase 1 study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors.
Adopted "emavusertib" as the generic name for CA-4948 and introduced "TakeAim" as brand name for related clinical trials.
Strong balance sheet with $139.8 million in cash, cash equivalents and investments at December 31, 2021; expected to maintain planned operations into 2024.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...